Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

OPTR...Receives Milestone Payment From Cempra for Next-Generation Macrolide Antibiotic

|Includes:Optimer Pharmaceuticals, Inc. (OPTR)

OPTR's drug nearest to approval is fidaxomicin, a promising treatment for C. diff infection which is a growing problem with only a couple of current drug treatments.  Next in line is Purvel for infectious dirrahea.  Both these have completed two phase 3 trials.

The news regarding a next generation macrolide was a bit of a surprise.  A successful phase one study resulted in a $500,000 payment to OPTR from Cempra Pharmaceuticals per a licensing agreement. 

The company has promising drugs, but still a ways to go.  How to value the company is problematic and the stock price has been steadily dropping since mid March and trades near its one year low.

Stocks: OPTR